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Abstract
Background:  The planned nationwide implementation of mammography screening 2007 in Germany will
increase the occurrence of mammographically detected breast abnormalities. These abnormalities are normally
evaluated by minimal invasive core biopsy. To minimize false positive and false negative histological findings, quality
assurance of the pathological evaluation of the biopsies is essential. Various guidelines for quality assurance in
breast cancer diagnosis recommend applying the B-classification for histopathological categorization. However,
to date there are only few studies that reported results about reliability and validity of B-classification. Therefore,
objectives of our study are to determine the inter- and intraobserver variability (reliability study) and construct
and predictive validity (validity study) of core biopsy evaluation of breast abnormalities. This paper describes the
design and objectives of the DIOS Study.
Methods/Design: All consecutive asymptomatic and symptomatic women with breast imaging abnormalities
who are referred to the University Hospital of Halle for core breast biopsy over a period of 24 months are
eligible. According to the sample size calculation we need 800 women for the study. All patients in the study
population underwent clinical and radiological examination. Core biopsy is performed by stereotactic-,
ultrasound- or magnetic resonance (MR) guided automated gun method or vacuum assisted method. The
histopathologic agreement (intra- and interobserver) of pathologists and the histopathologic validity will be
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evaluated. Two reference standards are implemented, a reference pathologist and in case of suspicious or
malignant findings the histopathologic result of excision biopsy. Furthermore, a self administrated questionnaire
which contains questions about potential risk factors of breast cancer, is sent to the participants approximately
two weeks after core biopsy. This enables us to run a case-control-analysis (woman with breast cancer
histological verified after excision are defined as cases, woman without malignant breast lesions are defined as
controls) to investigate the predictive values of various risk factors on breast cancer risk.
Conclusion: The analysis of reliability and validity of the histopathological evaluation of core biopsy specimens
of breast abnormalities is intended to provide important information needed for a high quality in breast cancer
diagnostic and for planning of treatment strategies.
Background
The number of women with mammographic abnormali-
ties of the breast will considerably increase in Germany
especially in the coming years when the mammography
screening will be offered population-wide. In most of
these cases a breast biopsy with subsequent histological
evaluation is required. In general, a breast biopsy is rec-
ommended in patients with category IV (suspicious) or V
(highly suspicious) in breast imaging reporting and data
system (BI-RADS). If breast biopsy does not correlate with
radiological findings, a rebiopsy is recommended.
An excision biopsy is performed in case of malignant or
suspicious lesions. To minimize false positive or false neg-
ative histological findings, quality assurance of the patho-
logical evaluation of the biopsies is essential. Currently,
guidelines recommend to apply a pathology classification
scheme that includes five reporting categories (see table
1), the so-called B-classification [1,2]. Categories B1-B2
usually do not necessitate further invasive diagnostic
workup unless biopsies classified as B1 were uninterpret-
able or unrepresentative of the breast lesion according to
the imaging and clinical findings. It is essential that the
histological appearance in biopsies is compared with the
clinical and radiological findings in order to ensure that
the biopsy is representative. Categories B3-B5 usually
necessitates further invasive workup. The B-categories are
also recommended to be used among women with symp-
tomatic breast lesions [1]. The B-categories are not
designed to give a definitive diagnosis, although it is pos-
sible in the majority of cases.
The representativeness of the biopsy depends on the treat-
ing clinician/radiologist whereas the quality of the speci-
men preparation, staining and interpretation depends on
the pathologist. Misclassification of biopsies by the
pathologist may result in two main errors. Firstly, benign
biopsies (B1-B2) may be misclassified as biopsies that
implicate further invasive evaluation of the breast lesion
(B3-B5) ("false-positive rate"). For example, a pathologist
could mistakenly diagnose an apocrine atypia in lobules,
ducts, or sclerosing lesions as ductal carcinoma in situ
(DCIS). Secondly, lesions that implicate further invasive
evaluation of the breast lesion (B3-B5) may be misclassi-
Table 1: Reporting Categories of Needle Biopsies [2]
Category Terminology Meaning
B1 Normal tissue or uninterpretable Normal or unsatisfactory biopsy which is:
1) uninterpretable because of artefact*
2) composed of stroma only*
3) composed of normal breast tissue where normal appearances are felt to be 
inconsistent with findings on imaging and clinical examination*
B2 Benign Usual ductal hyperplasia, sclerosing adenosis, fiboradenoma, involutionary 
calcification, periductal mastitis, hamartoma
B3 Benign but of uncertain biological potential Papillomas, radial scars/complex sclerosing lesions, lobular intraepithelial 
neoplasia (LIN), atypical epithelial proliferation of ductal type (AEDT) 
depending on grade and extension sometimes B4, phylloides tumor
B4 Suspicious Changes suggestive of in situ or invasive malignancy but a categorical diagnosis 
cannot be made because of artefact or because the appearances are 
borderline
B5 Malignant
a) in situ
b) invasive
c) uncertain whether in situ or invasive
d) other malignancies
Unequivocal malignant process
*: indication for a second biopsy.BMC Cancer 2007, 7:100 http://www.biomedcentral.com/1471-2407/7/100
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fied as benign biopsies (B1-B2) which results in a lack of
further invasive diagnostic evaluation ("false-negative
rate"). Common causes of false-positive and negative
diagnoses are listed in table 2.
There are only few available studies on the reliability and
validity of the B-classification of pathological evaluation
of core biopsies among women with radiographic abnor-
malities as has been suggested by the EC Working Group
on Breast Screening Pathology or the NHSBSP but none of
this used B-classification to evaluate intraobserver reliabil-
ity. Britton et al. performed 202 core biopsies (1% of
women screened) [3]. For 111 women (55%) surgical his-
tological confirmation was obtained (101 malignant and
10 benign lesions). The remaining patients were either
returned to standard 3-yearly screening or early repeat
screening after one year. The absolute sensitivity (assum-
ing that all unbiopsied B5 results are carcinoma) was
89.3%, the complete sensitivity (including additionally
B3-B4 in the numerator of the sensitivity) was 93.2%, and
the specificity was 88.7%.
Ibrahim et al. studied the role of core biopsy in the preop-
erative assessment of impalpable breast lesions mainly
among women from the National Health Service Breast
Screening Programme (NHSBSP) using an extended B-cat-
egorization [4]. They considered women with B3b-B5 as
"positive" according to their extended B-categorization.
The true-positive cases were those confirmed as malignant
on subsequent open biopsy. Negative biopsies were
defined as those within the B2r, B2 and B3a categories.
The sensitivity of biopsies for malignancy was 87.7%,
with a specificity of 99.4%, and a positive predictive value
of 98.5%, based on the prevalence within the study pop-
ulation of 31.9%. However, their exclusion of B1 (normal
tissue) and definition of positive biopsies that excluded
B3a may have resulted in a too optimistic diagnostic per-
formance of the core biopsy: of the 18 false-negative biop-
sies, nine were classified as B1.
The diagnostic agreement in evaluation of core biopsy
specimen was investigated by Collins et al. in 2004 core
biopsies [5]. The diagnosis for each case was placed into
five categories, similar to B-classification: benign, atypical
ductal hyperplasia, lobular hyperplasia, DCIS or invasive
carcinoma. They observed an agreement of 96% (kappa =
0.90) between local and central pathologists.
In the context of a mammography screening pilot project
in Bremen, Germany, Bonk et al. investigated the agree-
ment in B-categorization of two pathologists [6]. They
reported an observed agreement of 90% between local
pathologists and a reference pathologist. However, the ref-
erence pathologist was not blinded against local patholo-
gists.
Lee et al. performed a study to investigate the predictive
value of the two borderline B-categories, B3 (uncertain
malignant potential) and B4 (suspicious of malignancy)
[7]. They found that patients who had B4 lesions had an
85% risk of invasive carcinoma or carcinoma in situ.
Patients with B3 diagnosed in core biopsy had a lower risk
of malignancy on further biopsy (25%). Similar results
were found by Dillon et al., who also investigated the cor-
relation of B3/B4 core biopsy findings with excision his-
tology to determine associated rates of malignancy [8].
A major problem of validation studies of the B-categoriza-
tion of breast biopsies originates from a lack of a reference
standard of the biopsy evaluation. The most valid refer-
ence standard would be a diagnostic surgical excision
biopsy. However, those women with B-categories B1-B2
most likely do not undergo any invasive workup so that
the reference standard information of these women is
missing and may bias validation results. Possible practical
solution of this problem is the composition of an inde-
pendent expert panel that can assign a final diagnosis to
each patient. Alternative approach is to follow up the clin-
ical course of each patient during a suitable predefined
period, in terms of an delayed-type cross-sectional study
design [9].
There are many factors that may influence the reliability
and validity of the pathological evaluation of core biop-
sies including age of the women, gynaecological history
(menopause status, hormone intake), prior clinical, radi-
ological or histological findings, size and type of the
lesion, the representativeness of the biopsy in relation to
Table 2: Common causes of false-positive and negative diagnoses of screen-detected core biopsies [1]
Causes of false-positive diagnoses - Sclerosing adenosis or radial scar mistakenly diagnosed as tubular carcinoma
- Apocrine atypia in lobules, ducts, or sclerosing lesions mistakenly diagnosed as DCIS
- Chronic inflammation mistakenly diagnosed as infiltrating lobular carcinoma
- Invasion mistakenly diagnosed in DCIS
- Radiotherapy effects mistakenly diagnosed as carcinoma
Causes of false-negative diagnoses - Tubular carcinoma mistakenly diagnosed as sclerosing adenosis or radial scar
- Infiltrating lobular carcinoma mistakenly interpreted as chronic inflammation or missed
- Radiotherapy effect with missed foci of carcinoma
- Metaplastic carcinoma mistakenly diagnosed as a stromal proliferation/fibroblastic scarBMC Cancer 2007, 7:100 http://www.biomedcentral.com/1471-2407/7/100
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the imaging findings and the quality of the preparation
and staining of the tissue. Therefore the primary aims of
the study are to evaluate the intra- and inter-observer var-
iability of the pathologic evaluation of core biopsies of the
breast, potential determinants of a disagreement within
and between pathologists, the validity (sensitivity, specif-
icity) of the pathologic evaluation and the potential deter-
minants of false-positive and false-negative findings.
By its very nature, the study design additionally enables us
to run a case-control-analysis (woman with breast cancer
histological verified after excision are defined as cases,
woman without malign breast lesions are defined as con-
trols). Hence we can additionally investigate the predic-
tive values of various risk factors on breast cancer risk.
Secondary objectives of the study are amongst others:
- to investigate predictive values of BI-RADS for malignant
findings in core biopsy and excision [10,11]
- to investigate the influence of breast density on breast
cancer risk [12]
- to reassess the hypothesis of Band et al. [13], related to
different influences of smoking on breast cancer depend-
ing on pre- or postmenopausal beginning of smoking.
Methods/Design
Study population
The study population compromises all women who
undergo image-guided core biopsy for evaluation of
breast abnormality at University Hospital of Halle over a
2-year period (April 2006 to March 2008) and give
informed consent for participation in the study inclusiv-
ing any follow-up evaluations related to the study. The
majority of women (> 90%) undergoing a mammogra-
phy-, ultrasound- or MR-guided biopsy are referred to
University of Halle from private outpatient radiologists
and gynaecologists because of symptomatic abnormalities
of the breast or for self-referred breast cancer screening,
that means for a mammography in symptomless women.
Women with principal residence outside of Germany or
insufficient command of German language are excluded
from the study.
Standardized Course of Diagnostic Work-up
Image-Guided Biopsy
The choice of the imaging method (mammography,
sonography, MR) and the biopsy technique (automated
gun methods or vacuum assisted method) for histological
work-up of suspicious breast abnormalities may depend
on the imaging method that makes the lesion detectable,
the size and kind of the lesion, the sensitivity and specifi-
city which is required, patient comfort and costs [1,2].
Generally, before a biopsy is recommended, a complete
diagnostic work-up of the suspicious breast lesion (e.g.
further mammographic views, sonography) is necessary.
Therefore, all clinical and imaging data from referred
patients have to be reviewed again. Further necessary clin-
ical and imaging assessments are performed at the Univer-
sity of Halle.
According to international guidelines, ultrasound-guided
core biopsy is the method of first choice because it is easier
to perform more comfortable for the patient and less
time-consuming than the x-ray guided techniques [1,2].
Vacuum-assisted stereotactic breast biopsy is indicated for
image-detected, non-palpable small masses with and
without microcalcifications and suspicious microcalcifi-
cations (BI-RADS IV and BI-RADS V, sometimes BI-RADS
III). Indications for MR-guided vacuum biopsy are
lesions, which are exclusively detected by MR.
Ultrasound-guided core biopsy is performed at University
of Halle by using a programmable automatic biopsy sys-
tem (Coaxial Achieve, Allegiance, 14 Gauge). To get
enough specimens for histopathology, the acquisition of
at least 5 cores should be routinely attempted. Ultrasound
guided vacuum biopsy (VacuFlash, BARD; 10 Gauge) is
used for small lesions. The acquisition of a large tissue vol-
ume promises an excellent diagnostic accuracy.
In order to get a high quality, the procedures and the doc-
umentations are standardized. The documentation of
ultrasound-guided procedures should include images of
the lesion before biopsy, the needle in front of the lesion
and the needle within the lesion and images after biopsy.
Stereotactic vacuum-assisted breast biopsy is performed
on a digital prone table (Fisher Imaging Stereotactic Prone
Table, Denver, CO) using 11 gauge or 8 gauge vacuum
probes (Mammotome, Endo-Surgery, Breast Care, Nor-
derstedt, Germany). In all cases, number of cores taken
should be no less than 20 (11 gauge probe) [14]. On the
basis of this principle (suction of tissue, while the needle
stays in the lesion), the acquisition of a large tissue vol-
ume is possible. As described within the interdisciplinary
consensus vacuum biopsy (VB), the procedure should
include the following steps [14]:
- before vacuum biopsy, two orthogonal mammograms
should be available
- access is chosen in a way that in case of malignancy the
excision of the biopsy channel is possible (access and
depth is documented for wire localization)BMC Cancer 2007, 7:100 http://www.biomedcentral.com/1471-2407/7/100
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- the following images are documented: scout, 15°images
for targeting, two pre- and post-fire-images, two images
with the cavity
- after VB a control mammogram is taken
- in case of microcalcifications a specimen radiograph is
necessary.
- in cases where the whole or a high proportion of the
mammographic lesion has been removed, a small metal
marker clip is deployed at the biopsy site.
MR-guided vacuum biopsy is performed on Siemens MR
scanners (Impact Expert and Vision) using a dedicated
breast biopsy coil and a VB-device (Mammotome, Ethicon
Endosurgery, Hamburg or BARD). More than 20 cores (11
Gauge vacuum biopsy needle -Ethicon Endosurgery- or
VacuFlash, BARD; 10 Gauge) should be acquired.
During the procedure the patient is placed in prone posi-
tion on the compression unit. The breast is fixed between
two plates. To reidentify the lesion, the entire breast is
measured before and after injection of contrast media.
Based on the MR images, coordinates for access to the
lesion are calculated. The pathway to the lesion is precut
by a rigid and thick needle. Then, a thinner needle, called
"substitute needle" is inserted into the breast to imitate
the position of the biopsy needle. After a control measure-
ment this "substitute needle" is replaced by the biopsy
needle and vacuum biopsy is performed in the usual way:
The representative removal is checked by scanning the
entire breast again before and after injection of contrast
media.
Table 3: Indication for immunhistochemical (IHC) staining
Differential diagnosis IHC
Ductal hyperplasia (DH) vs. atypical epitelproliferation of ductal type (AEDT), ductal carcinoma in 
situ (DCIS)
Cytokeratin (CK) 14, CK 8/18
DCIS vs. invasive carcinoma CK 14, smooth muscle actin (SMA), CK 8/18
Sclerosing lesions vs. invasive carcinoma CK 14, SMA
Myoepitheliale lesions CK 14, SMA
Design of the DIOS-Study* Figure 1
Design of the DIOS-Study*. 1: Validation study (construct validity); 2: Reliability study (interobserver); 3: Reliability study 
(intraobserver); 4: Validation study (criterion validity); * the planned follow-up is not integrated in this figure.
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Pathological Assessment
Figure 1 gives an overview of the study design. The "first"
or local pathologists, Institute of Pathology, University of
Halle, review the hematoxylin and eosin-stained (HE)
slides from paraffin-embedded blocks of the biopsy spec-
imens. For differential diagnosis or receptor determina-
tion immunhistochemical (IHC) staining is performed in
various cases. The result of pathological assessment by the
first, local pathologist is communicated to the treating cli-
nician, but for treatment decision also the diagnosis by
the reference pathologist is included. Thereafter, the HE
slides and blocks are sent to the reference pathologist,
Gerhard-Domagk-Institute of Pathology, University of
Münster. He reviews the slides and does a specific IHC
staining in differential diagnostic problems (table 3).
Subsequently results of the pathological assessment are
sent to the study centre. Here the results of the assessment
by the first pathologist are compared to reference pathol-
ogist. In case of disagreement a consensus conference is
organized. Thereafter, the treating clinicians are informed
about the diagnosis by the reference pathologist respec-
tively the consensus diagnosis.
The comparison of the primary and reference pathologists
enables us to calculate the sensitivity, specificity, and pre-
dictive values of the B-categorization in the context of the
construct validity. The construct reference, which has a
subjective component included, obviously is not a perfect
objective gold standard and there may be few misclassifi-
cation errors of the reference pathologists. Therefore, the
follow-up information of patients improves the reference
standard. The motive to choose the pathologist at Univer-
sity of Münster as a reference pathologist is the following:
he is an internationally well-known pathologist with a
special expertise in breast pathology, is one of the most
experienced pathologist of breast pathology in Germany
and is chair of the German Reference Center of Breast
Pathology.
A "second" pathologist from the Albertinen-Pathology
Hamburg, who is blinded to the evaluations of the first
pathologist, evaluates the identical set of slides that the
first pathologist has seen in order to assess the interob-
server reliability.
Finally, after at least 6 months, all pathologists will again
evaluate a random sample of the histological slides
blinded to their own first evaluation of the specimens. The
comparison of the repeated evaluation ensures the assess-
ment of intraobserver reliability.
All pathologists receive clinical data and basic data from
mammography and other imaging procedures (including
ultrasound and MR, if available) because this information
will be used by pathologists in a routine care situation as
well [15]. For women with microcalcification, radiogra-
phy of the biopsy will be provided to the pathologists.
For all biopsies with uncertain correlation of imaging and
histopathology, with uninterpretable tissue due to arte-
facts or with specimens containing only stroma, a
repeated biopsy or excision by open biopsy is necessary.
In order to discuss causes and further recommendations
all cases with non-representative pathology and cases of
malignancy are analysed by an interdisciplinary tumor
conference consisting of a gynaecologist, radiologist and
pathologist as well as other medical personnel.
After histopathological evaluation, it is documented,
whether the histopathological findings correlate with the
imaging findings. In case of malignancy, an open biopsy
is recommended. The result of excision biopsy will be
used as reference standard in validation of suspicious or
malign core biopsy findings.
Consensus conference about discordant evaluations
In a consensus meeting at the end of the recruitment
period, discordant pathology evaluations of the first, sec-
ond or reference pathologist are reviewed among an
expert panel consisting of the participating pathologists,
radiologists and treating clinicians. Reasons for disagree-
ment will be assessed and analyzed.
Postal Questionnaire
A self-administered questionnaire, which contains ques-
tions about potential risk factors of breast cancer, is sent
to the participants approximately two weeks after biopsy.
It is sent back via reply-paid envelope.
Follow-up
For women who underwent an open excision shortly after
the core biopsy the reference standard is the histopatho-
logical examination of the excision material. According to
guidelines [14], women who underwent a stereotactic vac-
uum-assisted breast biopsy without a consecutive excision
surgery routinely undergo control examinations, typically
mammography guided examinations after about 6
months. In case of ultrasound or MR guided biopsy a sim-
ilar procedure is implemented.
In addition, the treating physician outside the hospital is
asked to do a mammography three years after biopsy.
Depending on the core biopsy technique used at entry
into the study, women also undergo an ultrasound exam-
ination of the breast (for those women with ultrasound-
guided core biopsy at entry) or MR of the breast (for those
women with MR-guided vacuum biopsy at entry) three
years after entry into the cohort. At the end of the follow-
up period, women with newly diagnosed breast lesionsBMC Cancer 2007, 7:100 http://www.biomedcentral.com/1471-2407/7/100
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will be compared with the imaging findings at entry into
the cohort. The follow-up of these women is meant as an
outlook. Currently, the study grant does not include the
financial support for the follow-up.
Data collection – case report forms and questionnaire
In general, for the data collection, standard case report
forms (CRF's) are used if available.
The radiological CRFs are based on the BI-RADS lexicon
classification form [16]. At least two different CRFs are
completed, a CRF for mammographic findings and a CRF
for documentation of the biopsy. In case of MR- or ultra-
sound-guided biopsy an additional CRF is completed. The
following items are routinely documented: localisation
technique (palpation, mammography, MR, ultrasound),
used biopsy technique (device, needles), number of
scores, breast density, mass shape, margin, calcification,
architectural distortion, special cases, location and size of
the lesion, total BI-RADS assessment and recommenda-
tion for further procedure.
All pathologists filling out a CRF with information to kind
of benign and malign lesions, histological calcification,
histological grading in case of invasive cancer, B-classifica-
tion, level of safety of B-category, quality of slides, details
of the evaluation, need for immunhistochemical staining.
If IHC staining is performed, a separate section of the CRF
is completed.
The self-administered questionnaire contains questions
about sociodemographic data, prior breast lesions, prior
breast biopsies, prior breast cancer, breast related symp-
toms, prior radiotherapy of the breast, menopause status
(menopause: no/yes, last period), pregnancies, familial
breast cancer, hormone intake, smoking history, nutrition
habits, alcohol drinking, health status, anthropometric
data, comorbidity, patient satisfaction and kind/location
of treatment after biopsy.
Quality control, training, certification of study personnel 
and data quality management
For reasons of quality assurance, all participating pathol-
ogists received a training set of histological slides, pro-
vided by the reference pathologist that contains 20 cases
of all kinds of breast pathologies. These slides were evalu-
ated and a B-categorization was assigned. Thereafter, the
categorization was compared with the diagnosis provided
by the reference pathologist. All disagreements were dis-
cussed by participating pathologists during a kick-off
meeting.
In order to ensure a highly standardized data collection,
all study personnel is specifically trained for the study pro-
cedures. Standard Operating Procedures (SOPs) have
been written for all workflows.
All paper documentation is double entered in order to
minimize errors due to data entry. Visual and computer-
ized plausibility checks are performed to detect possible
data entry errors of CRF and questionnaire documenta-
tion.
After selection of questionnaire- and CRF- items and plan-
ning of logistic procedures, a pretest was performed to test
instruments and logistics of data collection. Slight modi-
fications were made before recruitment of the study sub-
jects started.
The planning of the DIOS-Study was performed under
consideration of the GEP (Good Epidemiological Prac-
tice) and the STARD – initiative guidelines [17,18].
Statistical analysis
The agreement between two pathologists who independ-
ently evaluate the core biopsy material will be calculated
as observed agreement and chance-corrected agreement
(kappa). To assess validity of the B-categorization of first
pathologist compared to the reference standard (reference
pathologist respectively result of excision histology),
standard measures for diagnostic tests (sensitivity, specif-
icity, positive and negative predictive value) are calcu-
lated.
The case-control analysis includes the calculation of fre-
quency distributions and the estimation of odds ratios
(OR) by unconditional logistic regression analyses. 95%
confidence intervals (CI) are calculated to evaluate the
precision of the estimates.
All statistical analyses will be performed with SAS, Version
9.1 (SAS Institutes, Cary, NC).
Sample size calculation
The sample size calculation was done according to the pri-
mary outcome "Agreement of two pathologists relating to
B-classification". Assuming a conservative proportion of
true B3-B5 of about 0.20, a kappa of 0.80 and a distance
from kappa to the confidence limit of 0.05, we will need
about 886 patients. If the chance-corrected agreement
would be larger, smaller sample sizes would be required.
The assumed proportion of expected successes of 0.20 is a
conservative assumption which has been taken as a safe-
guard against the type-II-error. Within the NHSBSP the
prevalence of malignant breast disease was 31.9% [4]. In
the Netherlands Screening Program, Verkooijen et al.
found a prevalence of 37% of malignant breast disease
[19]. Previous German experiences with the vacuum-BMC Cancer 2007, 7:100 http://www.biomedcentral.com/1471-2407/7/100
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assisted biopsy showed that about 22% of the women
undergoing biopsy had an invasive carcinoma or an in-
situ carcinoma [20].
For the validation study part (construct validity), we
assumed a high specificity of 90% and more and therefore
base our sample size calculations on the precision of the
estimate of the sensitivity. If we assume a 95% CI, a two-
sided calculation method, an expected conservative sensi-
tivity of 70% and a distance from the point estimate of the
sensitivity to the confidence limit of 0.05, we will need
about 323 women in the study. Therefore, the sample size
of the reliability study will be sufficient for the validation
study.
According to experiences of recent years, it is expected that
about 600 women per year undergo breast biopsies at the
University of Halle. Therefore, over a recruitment period
of 24 months, we expect about 1200 women with breast
biopsies. Due to exclusion criteria and refusals to partici-
pate, we expect about 800 women to participate.
Ethical Considerations
According to the German GEPs, all collected data is con-
sidered to be confidential [17]. Therefore, each patient in
the study will be assigned a numeric primary key (identi-
fier) so that thereafter, case report forms can be ano-
nymized. The electronic data base of the study will not
contain personal data. In addition, the data base will be
protected by a password and only authorized study staff is
allowed to open the data base.
The study is a strictly observational study so that there are
no risks to declare. All eligible women will be informed
about the study and have to give an informed consent
before they can be included in the study.
The study was approved by the Ethics Committee of the
Medical Faculty of the Martin-Luther-University Halle-
Wittenberg, May 22nd, 2006.
Conclusion
With the analysis of reliability and validity of histopatho-
logical evaluation of core biopsy specimens of breast
abnormalities, the DIOS study is intended to contribute
important information needed for a high quality in breast
cancer diagnostic and for planning of treatment strategies.
The knowledge of factors, influencing the reliability and
validity of breast biopsy evaluation, are intended to use
for the planned German mammography screening. The
main goal of the study is to intensify the interdisciplinary
breast cancer research and to improve the transfer of
knowledge and results between different research divi-
sions.
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